title: Separating lentiviral vector injection and induction of gene expression in time, does not prevent an immune response to rtTA in rats.
abstract: BACKGROUND
  Lentiviral gene transfer can provide long-term expression of therapeutic genes such as erythropoietin. Because overexpression of erythropoietin can be toxic, regulated expression is needed. Doxycycline inducible vectors can regulate expression of therapeutic transgenes efficiently. However, because they express an immunogenic transactivator (rtTA), their utility for gene therapy is limited. In addition to immunogenic proteins that are expressed from inducible vectors, injection of the vector itself is likely to elicit an immune response because viral capsid proteins will induce "danger signals" that trigger an innate response and recruit inflammatory cells.
  
  
  RESULTS
  We have developed an autoregulatory lentiviral vector in which basal expression of rtTA is very low. This enabled us to temporally separate the injection of virus and the expression of the therapeutic gene and rtTA. Wistar rats were injected with an autoregulatory rat erythropoietin expression vector. Two or six weeks after injection, erythropoietin expression was induced by doxycycline. This resulted in an increase of the hematocrit, irrespective of the timing of the induction. However, most rats only responded once to doxycycline administration. Antibodies against rtTA were detected in the early and late induction groups.
  
  
  CONCLUSIONS
  Our results suggest that, even when viral vector capsid proteins have disappeared, expression of foreign proteins in muscle will lead to an immune response.
authors.affiliation: Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands.
authors.forename: David M
authors.initials: DM
authors.lastname: Markusic
authors.forename: Dirk R
authors.initials: DR
authors.lastname: de Waart
authors.forename: Jurgen
authors.initials: J
authors.lastname: Seppen
mesh_terms: D000818:Animals; D004318:Doxycycline / Q000494:pharmacology; D004921:Erythropoietin / Q000008:administration & dosage; D015316:Genetic Therapy / Q000009:adverse effects* / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000276:immunology*; D007109:Immunity; D016086:Lentivirus / Q000235:genetics / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D015534:Trans-Activators / Q000276:immunology; D015533:Transcriptional Activation / Q000187:drug effects*; D014764:Viral Proteins / Q000276:immunology
chemical_list: D015534:Trans-Activators; D014764:Viral Proteins; D004921:Erythropoietin; D004318:Doxycycline